Category Archives: Treatments

rheumatoid arthritis treatment fda approved

FDA Approves a New Oral Drug for Moderate to Severe RA

People with moderate to severe rheumatoid arthritis (RA) who haven’t responded well to one or more tumor necrosis factor (TNF) inhibitor medications now have a new option. The U.S. Food and Drug Administration (FDA) recently approved baricitinib (Olumiant), a pill that is taken once a day.

Baricitinib is a targeted disease-modifying antirheumatic drug (DMARD) that blocks Janus kinase (JAK), a group of enzymes that enable inflammatory signals to be activated inside a cell. It’s the second in this class of drug to hit the market for the treatment of RA; tofacitinib (Xeljanz) was the first, approved in 2012.

“It’s not a biologic but a ‘small molecule,’ or oral, targeted agent, that is highly effective in treating the signs and symptoms of RA,” explains Paul Howard, MD, a rheumatologist in Scottsdale, AZ. It is expected to be significantly cheaper than biologic medications.  Continue reading FDA Approves a New Oral Drug for Moderate to Severe RA

eating fish rheumatoid arthritis

RA Research Briefs: Tofacitinib, Fish, Remission

Keep up-to-date on the latest rheumatoid arthritis (RA) research with our brief research summaries.

Tofacitinib Plus Methotrexate May Work As Well As Biologic

If methotrexate (MTX) alone fails to control RA, adding the oral Janus kinase (JAX) inhibitor tofacitinib (Xeljanz) may be as effective as the standard practice of adding a biologic. The JAX inhibitor belongs to the third category of disease-modifying antirheumatic drugs (DMARDs) called targeted DMARDs. In a study of 1,146 patients with rheumatoid arthritis that had not adequately responded to MTX alone, approximately a third were switched to tofacitinib, while the others received either tofacitinib or the biologic adalimumab (Humira) along with methotrexate. At 6 months, only 38% of the patients receiving tofacitinib mono­therapy achieved ACR50 – 50 percent improvement – while 46% of patients that received tofacitinib and MTX achieved that response. Forty-four percent of patients who combined adalimubab with MTX achieved the similar improved response of the tofacitnib and MTX group.

SOURCE: The Lancet, July 2017  Continue reading RA Research Briefs: Tofacitinib, Fish, Remission

rheumatoid arthritis research briefs remission exercise

RA Research Briefs: Remission, Biologics, Exercise

Keep up-to-date on the latest rheumatoid arthritis (RA) research with our brief research summaries.

Smoking, Obesity Make RA Harder to Control

Remission in RA patients can be harder to achieve in those who are overweight or smoke, according to a recent study. American and Canadian researchers who collected data on more than 1,100 patients receiving standard treatment for RA found that sex (being female), excess weight and smoking were not significantly associated with symptom severity early on. However, all three factors influenced how much symptoms improved over time. The most dramatic differences in symptoms were seen in patients who were overweight or obese and smoked, the study found.

Source: ACR/ARHP Annual Meeting, November 2016

Continue reading RA Research Briefs: Remission, Biologics, Exercise

rheumatoid arthritis green tea

RA Research Briefs: Remission, Surgery, Green Tea

Keep up-to-date on the latest rheumatoid arthritis (RA) research with our brief research summaries.

Obesity Reduces Odds of RA Remission

Research suggests weight may be a factor in whether people with RA will achieve disease remission. A review of studies screened a total 3,368 patient records. Canadian researchers found obese patients with RA were less likely to achieve remission or sustain remission compared to healthy-weight patients. Obesity, they reported, negatively impacts disease activity and patient-reported outcomes during therapy. Therefore, they say, interventions to reduce BMI should be investigated for the ability to improve disease outcomes.

Source: Arthritis Care & Research, January 2017

Continue reading RA Research Briefs: Remission, Surgery, Green Tea

rheumatoid arthritis lab tests

Rheumatoid Arthritis Research Briefs: RA Tests, Dementia, Disability

Keep up-to-date on the latest rheumatoid arthritis (RA) research with our brief research summaries.

Obesity May Affect RA Tests

Research has shown that obesity can increase the risk of RA or worsen symptoms. A new study of more than 2,000 people with RA suggests it could also affect the results of tests used to measure RA inflammation.

Researchers at the University of Pennsylvania found a link between body mass index (BMI, a measure of body fat) and elevated results of two common tests – SED rate and C-reactive protein (CRP) – used in diagnosing RA and gauging its activity. Researchers say this association is related to fat mass and not RA disease activity. Doctors should consider a patient’s BMI when interpreting lab results.

Source: Arthritis Care & Research, published online April, 2017

Continue reading Rheumatoid Arthritis Research Briefs: RA Tests, Dementia, Disability

rheumatoid arthritis biologic tapering

Research Identifies Which RA Patients May Successfully Reduce Their Biologics

A new study presented recently at the 2017 Annual Meeting of the American College of Rheumatology identifies four factors that may predict which rheumatoid arthritis (RA) patients might successfully taper the dose of their biologic medication.

Although biologics are highly effective in controlling RA and its symptoms, patients in some cases prefer not to use them. Past studies have shown that it is possible to taper and even stop the medication in certain patients who are in remission once they have been successfully treated with one of these drugs.

Continue reading Research Identifies Which RA Patients May Successfully Reduce Their Biologics

rheumatoid arthritis treatment to prevent joint deformities

Aggressive RA Treatment May Prevent Joint Deformities

Thanks to earlier diagnosis and more effective treatments, joint deformities in people with rheumatoid arthritis (RA) are becoming less frequent and severe.

What Causes Joint Deformities in RA?

In a joint affected by RA, inflammatory cells of the immune system gather in the lining of the joint (called synovium), forming a fibrous layer of abnormal tissue (called pannus). The pannus releases substances that quicken bone erosion, cartilage destruction and damage to the surrounding ligaments. The involved joints lose their shape and alignment, resulting in deformities. Severe deformities lead to loss of joint function and the need for joint replacement surgery.

Continue reading Aggressive RA Treatment May Prevent Joint Deformities

fish rheumatoid arthritis

Eating Fish May Relieve RA

Eating fish at least twice a week may help reduce inflammation and joint pain in people with rheumatoid arthritis (RA), according to a new analysis published recently in Arthritis Care & Research.

Fish oil supplements have long been known to improve pain as well as increase remission rates in RA patients taking triple therapy. This is among the first studies to show that fish itself – with lower concentrations than supplements of the active ingredients, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) – may be just as good.

But, the study authors say more studies are needed, noting, “…we cannot draw firm conclusions about the impact of frequent fish consumption on RA activity.”

Continue reading Eating Fish May Relieve RA

Fibromyalgia and RA

RA With a Side of Fibromyalgia

For years, fibromyalgia was a mystery illness. No one knew what caused it, how to diagnose it or how best to treat it. Some people, including doctors, even questioned its existence. In the last few years, however, researchers have cleared up some of the mystery. Although much about fibromyalgia still isn’t understood completely, two things are clear: It’s very real, and it affects a disproportionate number of people with rheumatoid arthritis (RA).
Continue reading RA With a Side of Fibromyalgia